Cite
HARVARD Citation
Tjalma, W. et al. (2018). Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit. European journal of obstetrics, gynecology, and reproductive biology. pp. 46-51. [Online].